CTOs on the Move


 
Ambys Medicines is a biotechnology company focused on discovering and developing regenerative and restorative therapies for people with advanced liver disease. Founded by world-renowned experts in liver disease and regenerative medicine, Ambys is pioneering the application of novel modalities including cell and gene therapy, and gain-of-function drug therapy, to meet the urgent need for treatments that have the potential to restore liver function and prevent the progression to liver failure across multiple liver diseases that are untreatable or poorly treated today. Ambys was launched in 2018 by Third Rock Ventures and Takeda Pharmaceuticals with $140M in starting capital and is ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.ambys.com
  • 131 Oyster Point Boulevard Suite 200
    South San Francisco, CA USA 94080
  • Phone: 650.481.7662

Executives

Name Title Contact Details
Alan Smith
Chief Technology Officer Profile

Funding

Ambys raised $60M on 08/08/2018
Ambys raised $80M on 08/08/2018

Similar Companies

NephroGenex

NephroGenex is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Codagenix

Codagenix Inc. is a clinical stage biotechnology company with vaccine products against influenza, respiratory syncytial virus, dengue virus, and others currently under development. Codagenix uses a computer-based algorithm, called SAVE (Synthetic Attenuated Virus Engineering) to design viral genomes that are identical to the wild type strain at the amino acid level, but make less protein in human cells.

Brampton Cosmetic Surgery

Brampton Cosmetic Surgery is a Brampton, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

EndGenitor Technologies

EndGenitor Technologies is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ThermoGenesis Holdings

ThermoGenesis Holdings, Inc. is an industry leader in the development and commercialization of automated cell processing technologies for the cell and gene therapy fields. We offer a full suite of solutions for automated clinical biobanking, point-of-care applications, and large scale cell processing and manufacturing for the emerging CAR-T immunotherapy market.